Cargando…
Identification and Characterization of Mortaparib(Plus)—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms
SIMPLE SUMMARY: Functional inactivation of tumour suppressor protein p53 is frequently found in a large variety of cancers. One of the mechanisms by which p53 is inactivated is through its interaction with mortalin protein that inhibits its translocation, and hence the function, in the nucleus. Abro...
Autores principales: | Sari, Anissa Nofita, Elwakeel, Ahmed, Dhanjal, Jaspreet Kaur, Kumar, Vipul, Sundar, Durai, Kaul, Sunil C., Wadhwa, Renu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921971/ https://www.ncbi.nlm.nih.gov/pubmed/33671256 http://dx.doi.org/10.3390/cancers13040835 |
Ejemplares similares
-
Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
por: Meidinna, Hazna Noor, et al.
Publicado: (2022) -
Mutant p53(L194F) Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib(Plus), a Multimodal Small Molecule Inhibitor
por: Elwakeel, Ahmed, et al.
Publicado: (2021) -
Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and Mortaparib(Plus)
por: Kumar, Vipul, et al.
Publicado: (2021) -
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
por: Putri, Jayarani F., et al.
Publicado: (2019) -
Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53(Y220C) mutant: bioinformatics and experimental evidence
por: Radhakrishnan, Navaneethan, et al.
Publicado: (2021)